A#2531 @AlisaMueller CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm Are there gene depletions that affect inflamm pathways? 👉SIX1 reduces inflamm potentiation 👉NFIL3 deletion promotes inflamm, degradation @RheumNow #ACR24 https://t.co/Nqghb5UaBR

A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6

#ACR24 Guidelines #LupusNephritis for refractory dz @RheumNow https://t.co/LlSixkggKK

Imaging in TAK Diagnosis @KQuinnRheum @RheumNow ⭐ Take homes ⭐ 👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK 👉FDG PET -focal uptake in TAK vs diffuse in GCA 👉MRI good surrogate for disease activity where PET unavailable #ACR24 https://t.co/UWxTAZScIt

Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA). Key findings: - 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs. - Female patients and those with depression were more likely to be recalcitrant. - No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ

#ACR24 - Featured Industry Presentations Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo

The precise mechanism of action of GIOP is not known. Decrease in osteocyte LCN is observed. Abstr#2528 @RheumNow #ACR24 https://t.co/fazUUy03fQ

In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd

A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA

Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66